Boons, Christel C. L. M.;
den Hartog, Yvonne M.;
Janssen, Jeroen J. W. M.;
Zandvliet, Anthe S.;
Vos, René M.;
Swart, Eleonora L.;
Hendrikse, N. Harry;
Hugtenburg, Jacqueline G.
Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Food‐effect study of nilotinib in chronic myeloid leukaemia (NiFo study): Enabling dose reduction and relief of treatment burden
Beteiligte:
Boons, Christel C. L. M.;
den Hartog, Yvonne M.;
Janssen, Jeroen J. W. M.;
Zandvliet, Anthe S.;
Vos, René M.;
Swart, Eleonora L.;
Hendrikse, N. Harry;
Hugtenburg, Jacqueline G.
Erschienen:
Wiley, 2020
Erschienen in:
European Journal of Haematology, 105 (2020) 2, Seite 148-155
Sprache:
Englisch
DOI:
10.1111/ejh.13418
ISSN:
0902-4441;
1600-0609
Entstehung:
Anmerkungen:
Beschreibung:
AbstractObjectivesTaking advantage of its food‐dependent bioavailability, the present study investigated the effect of a reduced dose taken with real‐life meals on the pharmacokinetics (PK) of nilotinib in chronic myeloid leukaemia (CML) patients.MethodsNilotinib was taken fasted (300 mg BID, days 1‐4) or with real‐life meals (200 mg BID, days 5‐11). Rich sampling (days 1, 3, 8, 11) allowed for non‐compartmental PK analysis. Nilotinib exposure (AUC0–12 h ‐Cmin ‐Cmax) and its intra‐ and interpatient variability were compared between the two regimens. Adverse events were recorded by means of a patient diary and ECG monitoring.ResultsFifteen patients aged 40‐74 years participated. Nilotinib PK following 200 mg BID taken with a meal strongly resembled that of 300 mg BID taken fasted (Cmin percentile (P)10‐P90: 665‐1404 ng/mL and 557‐1743 ng/mL, respectively). Meals delayed nilotinib absorption. Intra‐ and interpatient variability were not increased by intake with meals. Nilotinib with food was well tolerated.ConclusionWith support of therapeutic drug monitoring, the use of a reduced 200 mg nilotinib dose with real‐life meals seems feasible and safe. Future (confirmatory) studies should further explore the usefulness of nilotinib dosing together with food, including the relationship with treatment efficacy as well as long‐term effects on quality of life.Clinical Trial Registration: NTR5000 (Netherlands Trial Register, www.trialregister.nl).